Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
APGE
HOLDApogee Therapeutics, Inc. · Healthcare · United States · $10.2B · Avg Vol: $590M/d
COMPANY DESCRIPTION
Apogee Therapeutics, Inc. is a biotechnology company focused on developing novel antibody therapeutics for inflammatory and immunological diseases, with a pipeline targeting conditions like atopic dermatitis and COPD. The company aims to differentiate its antibody candidates through enhanced potency, half-life, and novel mechanisms of action to improve upon existing treatments. Apogee is a clinical-stage biotech firm strategically developing next-generation biologics for chronic inflammatory diseases, leveraging advanced antibody engineering.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 9.1M | 12.5M | — |
| EPS | -1.46 | -3.36 | -3.30 | -3.74 | — | -4.33 | -4.41 | -5.19 | — |
| Shares | 48.0M | 48.5M | 59.5M | 68.4M | +42.5% | 62.1M | — | — | — |
| Debt | 0 | 2.0M | 11.8M | 8.8M | 108.6% | 8.0M | — | — | — |
| Equity | 0 | 379.9M | 716.8M | 903.9M | 54.2% | — | — | — | — |
| Op CF | -16.4M | -74.8M | -171.2M | -227.4M | — | -234.5M | — | — | — |
| Inv CF | 0 | -273.9M | -300.5M | -179.6M | — | — | — | — | — |
| Fin CF | 168.3M | 315.4M | 495.1M | 396.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of APGE are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| APGE | Apogee Therapeutics, Inc.(you) | $10.2B | 41 | HOLD |
| 0JXI.L | Madrigal Pharmaceuticals, Inc. | $11.0B | 43 | HOLD |
| IMVT | Immunovant, Inc. | $8.1B | 39 | HOLD |
| AXSM | Axsome Therapeutics, Inc. | $12.4B | 44 | HOLD |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $12.1B | 36 | HOLD |
| PTGX | Protagonist Therapeutics, Inc. | $8.8B | 50 | HOLD |
| SYRE | Spyre Therapeutics, Inc. | $8.9B | 32 | SELL |
| NUVL | Nuvalent, Inc. | $9.8B | 30 | SELL |
| MIRM | Mirum Pharmaceuticals, Inc. | $6.9B | 47 | HOLD |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.9B | 30 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%